|
1
|
Honkoop AH, van Diest PJ, de Jong JS, Linn
SC, Giaccone G, Hoekman K, Wagstaff J and Pinedo HM: Prognostic
role of clinical, pathological and biological characteristics in
patients with locally advanced breast cancer. Br J Cancer.
77:621–626. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Medimegh I, Omrane I, Privat M, Uhrhummer
N, Ayari H, Belaiba F, Benayed F, Benromdhan K, Mader S, Bignon IJ,
et al: MicroRNAs expression in triple negative vs non triple
negative breast cancer in Tunisia: Interaction with clinical
outcome. PLoS One. 9:e1118772014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rakha EA, Elsheikh SE, Aleskandarany MA,
Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet
JS, Akslen LA, et al: Triple-negative breast cancer: Distinguishing
between basal and nonbasal subtypes. Clin Cancer Res. 15:2302–2310.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishikawa T, Shimizu D, Kito A, Ota I,
Sasaki T, Tanabe M, Yamada A, Arioka H, Shimizu S, Wakasugi J, et
al: Breast cancer manifested by hematologic disorders. J Thorac
Dis. 4:650–654. 2012.PubMed/NCBI
|
|
5
|
Fausto P and Barni S: Benefit of tamoxifen
in estrogen receptor positive DCIS of the breast. Gland Surg.
1:3–4. 2012.PubMed/NCBI
|
|
6
|
Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki
JM, Cui X and Giuliano AE: Personalizing breast cancer staging by
the inclusion of ER, PR, and HER2. JAMA Surg. 149:125–129. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Andrés R, Pajares I, Balmaña J, Llort G,
Ramón Y, Cajal T, Chirivella I, Aguirre E, Robles L, Lastra E,
Pérez-Segura P, et al: Association of BRCA1 germline mutations in
young onset triple-negative breast cancer (TNBC). Clin Transl
Oncol. 16:280–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu H, Wang Y, Li X, Zhang YJ, Li J, Zheng
YQ, Liu M, Song X and Li XR: Expression and regulatory function of
miRNA-182 in triple-negative breast cancer cells through its
targeting of profilin 1. Tumour Biol. 34:1713–1722. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheang MC, Voduc D, Bajdik C, Leung S,
McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast
cancer defined by five biomarkers has superior prognostic value
than triple-negative phenotype. Clin Cancer Res. 14:1368–1376.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gelmon K, Dent R, Mackey JR, Laing K,
McLeod D and Verma S: Targeting triple-negative breast cancer:
Optimising therapeutic outcomes. Ann Oncol. 23:2223–2234. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Leva G and Croce CM: The role of
microRNAs in the tumorigenesis of ovarian cancer. Front Oncol.
3:1532013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Korpal M, Ell BJ, Buffa FM, Ibrahim T,
Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua
Y, et al: Direct targeting of Sec23a by miR-200s influences cancer
cell secretome and promotes metastatic colonization. Nat Med.
17:1101–1108. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei
Y, Li Y, Yang Q, Liu J, Wei JJ, et al: miR-145 inhibits tumor
growth and metastasis by targeting metadherin in high-grade serous
ovarian carcinoma. Oncotarget. 5:10816–10829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Link A, Kupcinskas J, Wex T and
Malfertheiner P: Macro-role of microRNA in gastric cancer. Dig Dis.
30:255–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du L and Pertsemlidis A: microRNA
regulation of cell viability and drug sensitivity in lung cancer.
Expert Opin Biol Ther. 12:1221–1239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wall NR: Colorectal cancer screening using
protected microRNAs. J Gastrointest Oncol. 2:206–207.
2011.PubMed/NCBI
|
|
17
|
Saus E, Soria V, Escaramís G, Vivarelli F,
Crespo JM, Kagerbauer B, Menchón JM, Urretavizcaya M, Gratacòs M
and Estivill X: Genetic variants and abnormal processing of
pre-miR-182, a circadian clock modulator, in major depression
patients with late insomnia. Hum Mol Genet. 19:4017–4025. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moskwa P, Buffa FM, Pan Y, Panchakshari R,
Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K,
Weinstock DM, et al: miR-182-mediated down-regulation of BRCA1
impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell.
41:210–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chiang CH, Hou MF and Hung WC:
Up-regulation of miR-182 by β-catenin in breast cancer increases
tumorigenicity and invasiveness by targeting the matrix
metalloproteinase inhibitor RECK. Biochim Biophys Acta.
1830:3067–3076. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guttilla IK and White BA: Coordinate
regulation of FOXO1 by miR-27a, miR-96 and miR-182 in breast cancer
cells. J Biol Chem. 284:23204–23216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li P, Sheng C, Huang L, Zhang H, Huang L,
Cheng Z and Zhu Q: miR-183/−96/−182 cluster is upregulated in most
breast cancers and increases cell proliferation and migration.
Breast Cancer Res. 16:4732014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aitola M, Carlsson P, Mahlapuu M, Enerbäck
S and Pelto-Huikko M: Forkhead transcription factor FoxF2 is
expressed in mesodermal tissues involved in epithelio-mesenchymal
interactions. Dev Dyn. 218:136–149. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirata H, Ueno K, Shahryari V, Deng G,
Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: microRNA-182-5p
promotes cell invasion and proliferation by down regulating FOXF2,
RECK and MTSS1 genes in human prostate cancer. PLoS One.
8:e555022013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang QS, Kong PZ, Li XQ, Yang F and Feng
YM: FOXF2 deficiency promotes epithelial-mesenchymal transition and
metastasis of basal-like breast cancer. Breast Cancer Res.
17:302015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pandey V, Perry JK, Mohankumar KM, Kong
XJ, Liu SM, Wu ZS, Mitchell MD, Zhu T and Lobie PE: Autocrine human
growth hormone stimulates oncogenicity of endometrial carcinoma
cells. Endocrinology. 149:3909–3919. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim YJ, Choi JS, Seo J, Song JY, Lee SE,
Kwon MJ, Kwon MJ, Kundu J, Jung K, Oh E, et al: MET is a potential
target for use in combination therapy with EGFR inhibition in
triple-negative/basal-like breast cancer. Int J Cancer.
134:2424–2436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pencheva N and Tavazoie SF: Control of
metastatic progression by microRNA regulatory networks. Nat Cell
Biol. 15:546–554. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang L, Liu T, Huang Y and Liu J:
microRNA-182 inhibits the proliferation and invasion of human lung
adenocarcinoma cells through its effect on human cortical
actin-associated protein. Int J Mol Med. 28:381–388.
2011.PubMed/NCBI
|
|
33
|
Weeraratne SD, Amani V, Teider N,
Pierre-Francois J, Winter D, Kye MJ, Sengupta S, Archer T, Remke M,
Bai AH, et al: Pleiotropic effects of miR-183~96~182 converge to
regulate cell survival, proliferation and migration in
medulloblastoma. Acta Neuropathol. 123:539–552. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Segura MF, Hanniford D, Menendez S, Reavie
L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A,
Bogunovic D, et al: Aberrant miR-182 expression promotes melanoma
metastasis by repressing FOXO3 and microphthalmia-associated
transcription factor. Proc Natl Acad Sci USA. 106:1814–1819. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C,
Wu J, Hu B, Cheng SY, Li M, et al: TGF-β induces miR-182 to sustain
NF-κB activation in glioma subsets. J Clin Invest. 122:3563–3578.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang W, Qian P, Zhang X, Zhang M, Wang H,
Wu M, Kong X, Tan S, Ding K, Perry JK, et al: Autocrine/paracrine
human growth hormone-stimulated MicroRNA 96–182-183. Cluster
promotes epithelial-mesenchymal transition and invasion in breast
cancer. J Biol Chem. 290:13812–13829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kong PZ, Yang F, Li L, Li XQ and Feng YM:
Decreased FOXF2 mRNA expression indicates early-onset metastasis
and poor prognosis for breast cancer patients with histological
grade II tumor. PLoS One. 8:e615912013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lam EW, Brosens JJ, Gomes AR and Koo CY:
Forkhead box proteins: Tuning forks for transcriptional harmony.
Nat Rev Cancer. 13:482–495. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles
of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mani SA, Yang J, Brooks M, Schwaninger G,
Zhou A, Miura N, Kutok JL, Hartwell K, Richardson AL and Weinberg
RA: Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis
and is associated with aggressive basal-like breast cancers. Proc
Natl Acad Sci USA. 104:10069–10074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi
SC and Yu Q: FOXQ1 regulates epithelial-mesenchymal transition in
human cancers. Cancer Res. 71:3076–3086. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shi W, Gerster K, Alajez NM, Tsang J,
Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, et al:
MicroRNA-301 mediates proliferation and invasion in human breast
cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kundu ST, Byers LA, Peng DH, Roybal JD,
Diao L, Wang J, Tong P, Creighton CJ and Gibbons DL: The miR-200
family and the miR-183~96~182 cluster target Foxf2 to inhibit
invasion and metastasis in lung cancers. Oncogene. 35:173–186.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yamamoto H, Oue N, Sato A, Hasegawa Y,
Yamamoto H, Matsubara A, Yasui W and Kikuchi A: Wnt5a signaling is
involved in the aggressiveness of prostate cancer and expression of
metalloproteinase. Oncogene. 29:2036–2046. 2010. View Article : Google Scholar : PubMed/NCBI
|
